glp-1 agonists cardiovascular diseases and mortality outcomes with receptor vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Cardiovascular Protection with a Long-Acting

Consult with a Qualified Professional First things first dont skip the consultation

36 Liraglutide seems to offer a body-weight loss of 46 kg compared to placebo, 37 while the protective effect on cardiovascular outcomes (lower rates of myocardial infarction, stroke and death) is notable, 38 as is the lower rates of diabetes nephropathy development and progression

It works by fitting directly into the lipid layers of skin to help restore structure and reduce transepidermal water loss (TEWL)

The ODT dissolves on the tongue for oral mucosal absorption

However, subsequent research has shown that carnitine acts to modulate thyroid hormones within our cells, so it can act like an agonist (a substance that initiates a response when combined with a receptor) helping thyroid hormone action in cases of hypothyroidism, and as an antagonist (blocker) in cases of hyperthyroidism